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Following publication of themanuscript, the authors identified an inadvertent error in the text associatedwith Figure 6D in the Results.
Although NFIB is associated with a super-enhancer, it was not part of the leading-edge gene set from the enrichment analysis
(Figures 6A and 6C). NFIB is not listed in Figure 6C, which displays the final filtered transcription factor gene list. Thus, Figure 6C
is correct and the error was confined to the text.
In addition, we inadvertently left out the full acknowledgment for a major funding institution for this project: the Bridge Project.
Thus, the previous acknowledgment text has been replaced with the following: ‘‘This work was also supported by the Bridge Project
(K.-K.W., N.S.G., and R.A.Y.), a collaboration between The Koch Institute for Integrative Cancer Research at MIT and the Dana-
Farber/Harvard Cancer Center (DF/HCC).’’
The online text has been corrected to reflect the above changes.Cancer Cell 27, 149, January 12, 2015 ª2015 Elsevier Inc. 149
